Which of the following is a treatment option for Multiple Sclerosis?

Multiple sclerosis (MS) is a chronic autoimmune disorder that affects the central nervous system, leading to a wide range of neurological symptoms. The management of MS includes both acute treatments for exacerbations and long-term disease-modifying therapies.

Beta-interferon is a well-established disease-modifying therapy for MS. It works by reducing the frequency and severity of relapses and has been shown to slow the progression of disability in patients with relapsing forms of MS. Beta-interferon modulates the immune response, decreasing inflammatory processes that contribute to demyelination and the formation of plaques in the central nervous system. Its efficacy in reducing relapse rates and delaying the progression of disability makes it a cornerstone treatment for managing this condition.

While corticosteroids are often used for the acute management of exacerbations in MS, they are not a long-term treatment option for the chronic management of the disease itself. Azathioprine can be used in some cases, particularly for progressive forms of MS, but it is not as commonly first-line as beta-interferon. Rituximab is an anti-CD20 monoclonal antibody that has been used off-label for MS, particularly in certain subtypes, but it is not a standard treatment regimen compared to beta-interferon